We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Hemosonics - A Stago Company

HemoSonics is a medical device company developing a point-of-care diagnostic platform to guide the management of crit... read more Featured Products: More products

Download Mobile App





HemoSonics Demonstrates Breakthrough in Point-Of-Care Viscoelastic Hemostasis Testing

By LabMedica International staff writers
Posted on 01 Aug 2024
Print article
Image: FDA recently granted HemoSonics expanded use of its critical bleeding management system with Special 510(k) clearance (Photo courtesy of HemoSonics)
Image: FDA recently granted HemoSonics expanded use of its critical bleeding management system with Special 510(k) clearance (Photo courtesy of HemoSonics)

At ADLM 2024, HemoSonics (Durham, NC, USA) is demonstrating its Quantra Hemostasis System which has the broadest range of FDA-cleared indications for use in its category and is cleared for use with arterial and venous blood samples in cardiac, trauma, liver, and major orthopedic surgery patients.

HemoSonics' Quantra Hemostasis System consists of the Quantra Hemostasis Analyzer with QPlus and QStat Cartridges, which enable clinicians to deliver patient-centered decisions on bleeding management that improve care and optimize blood product usage. The Quantra System is FDA-cleared for use in point-of-care settings such as operating rooms, intensive care units, and in hospital laboratories, enabling hospitals to standardize use institution-wide with greater operational efficiency. The Quantra System allows healthcare professionals to make individualized and evidence-based decisions on how to manage a bleeding patient and give a patient only medically appropriate therapy – an approach that supports global initiatives to reduce inappropriate transfusions of blood products.

The Quantra System requires minimal resources to maintain, is easy to operate and interpret, and provides fast, comprehensive whole-blood coagulation analysis at the point of care or in laboratory-based settings, typically in less than 15 minutes. A recent study showed that the implementation of the Quantra Hemostasis Analyzer with the QPlus Cartridge reduced utilization of blood components by up to 90%, allowing greater availability for those patients truly in need. In addition, the cost of blood products decreased by 41%. HemoSonics' QStat Cartridge used with the Quantra Hemostasis Analyzer first received 510(k) clearance from the U.S. FDA in 2022 for use in venous whole blood samples. In April this year, HemoSonics received Special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded use of arterial blood samples with its Quantra QStat Cartridge.

Related Links:
HemoSonics

New
Gold Member
ZIKA Virus Test
ZIKA ELISA IgG
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Human Chorionic Gonadotropin Test
Humasis hCG Combo
New
Flu Test
Influenza A/B Virus Detection Kit

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: TriVerity Test is the first and only molecular blood test that can both identify bacterial and viral infections (Photo courtesy of Inflammatix)

30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease

Despite significant investment in innovation and decades of research, sepsis continues to have a high mortality rate and remains the most expensive diagnosis for healthcare systems. Hospital systems bear... Read more

Industry

view channel
Image: The 24th edition of Medlab Middle East will be held from 3-6 February at the Dubai World Trade Centre (Photo courtesy of Informa Markets)

Medlab Middle East Looks to The Future of Laboratories

The medical laboratory market in the Middle East and Africa (MEA) is expected to experience substantial growth, with projections indicating it could reach USD 473.84 million by 2029, growing at a strong... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.